Eighteen-month androgen-deprivation therapy plus radiotherapy recommended standard for patients with high-risk prostate cancer

Reducing the duration of androgen-deprivation therapy with radiotherapy from 36 months to 18 months is safe and may represent a new standard of care for patients with high-risk prostate cancer, according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Prostate Cancer Advisor

Leave a Reply

  • (will not be published)

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>